SolaranRx Inc. is jumping on the theranostics bandwagon by tackling the deadly skin cancer melanoma, which for advanced cases has a staggering survival rate of only six months and a one-year mortality of 75%. The company’s lead compound, SRX-1177, is a novel peptide linked to a radioisotope that can preferentially attach to melanocortin-1, a unique receptor overexpressed on melanoma cells.

This month’s profile group, Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky, features profiles of EnBiotix, Nosopharm, and Spero Therapeutics. Plus these Start-Ups Across Health Care: Elute, Madison Vaccines, Monarch Medical Technologies, Niveus Medical, and SolaranRx.

SolaranRx Inc. is jumping on the theranostics bandwagon by tackling the deadly skin cancer melanoma, which for advanced cases has a staggering survival rate of only six months and a one-year mortality of 75%. The company’s lead compound, SRX-1177, is a novel peptide linked to a radioisotope that can preferentially attach to melanocortin-1, a unique receptor overexpressed on melanoma cells.

Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2014.